The impact of Girdin expression on recurrence-free survival in patients with luminal-type breast cancer

Kazumi Nishimae, Nobuyuki Tsunoda, Yukihiro Yokoyama, Toshio Kokuryo, Akari Iwakoshi, Masahide Takahashi, Masato Nagino

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

Background: In patients with luminal-type breast cancer (positive for ER and/or PgR), a complete consensus on the threshold indication for a combination of chemotherapy and endocrine therapy has not been achieved, especially for patients with HER2-negative luminal type (HNLT). Girdin, an actin-binding Akt substrate, plays a crucial role in the migration of cancer cells. This study examined the expression of Girdin in relation to clinicopathological features and other immunohistochemical markers (HER2, Ki-67), especially in patients with HNLT breast cancer. Methods: One hundred one breast cancer patients who underwent surgery were evaluated. Immunohistochemical staining was performed for Girdin and other biomarkers, such as ER, PgR, HER2, and Ki-67. Results: Positive expression of Girdin was observed in 26 patients. The expression of Girdin was significantly associated with the incidence of lymph node metastases (p = 0.001). Among the other examined biomarkers, positive expression of Ki-67 also showed a significant association with the incidence of lymph node metastases (p = 0.04). In the HNLT breast cancer patients (n = 73), the 5-year recurrence-free survival rate was significantly lower (57 %) in patients with positive expression of both Girdin and Ki-67 than the rate in other patients (92 %) (p = 0.002). Conclusion: This study demonstrated that the expression of Girdin in invasive breast cancer is strongly associated with lymph node metastasis. The expression status of Girdin and Ki-67 can be a useful biomarker in stratifying patients with HNLT breast cancer into those with high risk of recurrence and the need for additional chemotherapy.

Original languageEnglish
Pages (from-to)445-451
Number of pages7
JournalBreast Cancer
Volume22
Issue number5
DOIs
Publication statusPublished - 07-09-2015

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The impact of Girdin expression on recurrence-free survival in patients with luminal-type breast cancer'. Together they form a unique fingerprint.

Cite this